TIME Companies

Johnson & Johnson Ordered to Pay $55M in Talcum Powder Cancer Case

Johnson & Johnson's products are seen December 16, 2004 in New York.
Chris Hondros—Getty Images Johnson & Johnson's products are seen December 16, 2004 in New York.

The verdict follows a previous case in which the family of a woman who died of ovarian cancer was awarded $72 million

Pharmaceutical giant Johnson & Johnson has been ordered to pay $55 million to an American woman who says the company’s talcum powder caused her to develop ovarian cancer.

Following a three-week-long trial in Missouri, jurors decided on Monday in favor of Gloria Ristesund, Reuters reports. The 62-year-old plaintiff said she had used the company’s talc-based powders as feminine hygiene products for decades. According to her lawyers, she developed ovarian cancer and had to get a hysterectomy.

The decision follows a previous case in the same court in February, in which a family of a woman who died of ovarian cancer was awarded $72 million.

According to Reuters, the company is facing 1,2000 similar lawsuits, accusing the Johnson & Johnson of not adequately warning its consumers about the cancer risks to its talcum-based products, which include Baby Powder and Shower to Shower Powder.

J&J, reports Reuters, says its cosmetic talc is safe and that Monday’s verdict at the Missouri state court contradicts 30 years of research. The company intends to appeal the jury decision.

[Reuters]

Tap to read full story

Your browser is out of date. Please update your browser at http://update.microsoft.com


YOU BROKE TIME.COM!

Dear TIME Reader,

As a regular visitor to TIME.com, we are sure you enjoy all the great journalism created by our editors and reporters. Great journalism has great value, and it costs money to make it. One of the main ways we cover our costs is through advertising.

The use of software that blocks ads limits our ability to provide you with the journalism you enjoy. Consider turning your Ad Blocker off so that we can continue to provide the world class journalism you have become accustomed to.

The TIME Team